Precision medicine in gastric cancer

Cancer research · Gastric cancer · ERBB2 · TP53 · KRAS

Use of trastuzumab and ramucirumab, approved after phase III trials, as first‑ and second‑line targeted therapies for advanced gastric cancer.

Gastric cancer (GC) is a complex disease linked to a series of environmental factors and unhealthy lifestyle habits, and especially to genetic alterations. GC represents the second leading cause of cancer‑related deaths worldwide. Its onset is subtle, and the majority of patients are diagnosed once the cancer is already advanced. In recent years, there have been innovations in the management of advanced GC including the introduction of new classifications based on its molecular characteristics. Thanks to new technologies such as next‑generation sequencing and microarray, the Cancer Genome Atlas and Asian Cancer Research Group classifications have also paved the way for precision medicine in GC, making it possible to integrate diagnostic and therapeutic methods. Among the objectives of the subdivision of GC into subtypes is to select patients in whom molecular targeted drugs can achieve the best results; many lines of research have been initiated to this end. After phase III clinical trials, trastuzumab, anti‑Erb‑B2 receptor tyrosine kinase 2 (commonly known as ERBB2) and ramucirumab, anti‑vascular endothelial growth factor receptor 2 (commonly known as VEGFR2) monoclonal antibodies, were approved and introduced into first‑ and second‑line therapies for patients with advanced/metastatic GC. However, the heterogeneity of this neoplasia makes the practical application of such approaches difficult. Unfortunately, scientific progress has not been matched by progress in clinical practice in terms of significant improvements in prognosis. Survival continues to be low in contrast to the reduction in deaths from many common cancers such as colorectal, lung, breast, and prostate cancers. Although several target molecules have been identified on which targeted drugs can act and novel products have been introduced into experimental therapeutic protocols, the overall approach to treating advanced stage GC has not substantially changed. Currently, surgical resection with adjuvant or neoadjuvant radiotherapy and chemotherapy are the most effective treatments for this disease. Future research should not underestimate the heterogeneity of GC when developing diagnostic and therapeutic strategies aimed toward improving patient survival.

The application of precision medicine, through the identification of molecular subtypes and the use of targeted agents such as trastuzumab and ramucirumab, offers the potential to improve outcomes for patients with advanced gastric cancer. However, persistent heterogeneity and late diagnosis continue to limit clinical benefit, underscoring the need for better risk stratification and novel therapeutic approaches.

Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.

Original source

Related signals